Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Halozyme Therapeutics Inc.

www.halozyme.com

Latest From Halozyme Therapeutics Inc.

Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III

The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.

Business Strategies Clinical Trials

Ninlaro Failure Leaves Little In AL Amyloidosis Pipeline

Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.

Clinical Trials Rare Diseases

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO

News and views from day four of the BIO International Convention: emerging company M&A deals nearly double in 2018; former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; and the ASCO effect on the 3-6 June BIO meeting.

Drug Review Review Pathway

BIO 2019 Notebook: Lartruvo Lookback, M&A Soars, BIO Vs. ASCO

News and views from day four of the BIO International Convention: Former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; emerging company M&A deals nearly double in 2018; and the ASCO effect on the 3-6 June BIO meeting.

Drug Review Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Hyalozyme Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Halozyme Therapeutics Inc.
  • Senior Management
  • Helen Torley, Pres. & CEO
    Laurie Stelzer, SVP, CFO
    Benjamin Hickey, SVP, Chief Commercial Officer
    Dimitrios Chondros, SVP, CMO
    Alison A Armour, MD, SVP, R&D
  • Contact Info
  • Halozyme Therapeutics Inc.
    Phone: (858) 794-8889
    11388 Sorrento Valley Rd.
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register